{"schema_version":"secwatch.filing_event.v1","accession":"0001708599-25-000076","form_type":"8-K","ticker":"SER","cik":"0001708599","company_name":"Serina Therapeutics, Inc.","filed_at":"2025-07-29T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.734895+00:00","generated_at":"2026-05-17T23:44:38.581256+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Serina advances SER-270 (POZ-VMAT2i) once-weekly injectable into TD development","bullets":["SER-270 is a long-acting, once-weekly subcutaneous VMAT2 inhibitor for tardive dyskinesia (TD).","U.S. TD market reached $3.7B in 2024; projected to grow to $5.4B by 2030.","Fewer than 30% of U.S. TD patients are diagnosed; less than half receive treatment.","Serina plans to explore POZ-VMAT2i for Huntington's chorea as a secondary indication.","CEO Steve Ledger to present at BTIG Virtual Biotechnology Conference on July 29, 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001708599-25-000076","json":"https://secwatch.observer/filing/0001708599-25-000076.json","markdown":"https://secwatch.observer/filing/0001708599-25-000076.md","text":"https://secwatch.observer/filing/0001708599-25-000076.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1708599/000170859925000076/0001708599-25-000076-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1708599/000170859925000076/ser-20250729.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T23:44:38.581256+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}